Former District Commander John Price accused of bullying, another foggy morning disrupts Auckland flights and Princess Anne sustains minor injuries. Video / NZ Herald
Some cancer patients say the Government’s treatment pledge comes too late – while others are still in the dark about whether game-changing drugs will be funded for them.
Auckland resident Mandy Grantley has stage four bowel cancer. The 57-year-old has paid $100,000, funded by a Givealittle page, for two rounds of cetuximab.
The drug will now be funded, but she fears it may be too late.
The drug has kept her cancer at bay for three years, and it has been an exhausting wait to find out if the cost pressures will be eased, Grantley – who is also a patient advocate for Bowel Cancer New Zealand – said.
“Fund the drugs now, you already promised it back in November, it’s going to be a year before they’ve done anything.”
Prime Minister Christopher Luxon said about 175,000 people will benefit from the newly funded treatments in the first 12 months.
That includes seven of the 13 drugs promised before the election – but which have not been guaranteed until now.
“As I said at the time, I think we could have communicated it better, but what’s exciting is we talked about 13 cancer treatments and now we have 26 cancer treatments,” Luxon said.
Specific treatments for bowel, liver, kidney, lung and bladder cancer have been named.
“Our hope would be – and some of the phasing would be – that if we’ve started in October and November this year, that within a year we’ve rolled out most of these other medicines.”
Reti said Pharmac will need to go through its procurement process.
Treatments for other cancers, such as blood cancer and breast cancer, will also be funded. The details of these haven’t been announced yet. Pharmac will decide that.
Stuart Edwards would like to see Daratumumab funded by Pharmac. Photo / RNZ, Angus Dreaver
Wairarapa resident Stuart Edwards, 50, has multiple myeloma. He said he is crossing his fingers that the life-changing drug he needs – daratumumab – will be funded.
“Daratumumab is something that can be seen, not quite as curative, but as having a really significant impact on life and productivity, and that’s been demonstrated without doubt,” Edwards said.
“It’s not there as a pain management tool, it’s a tool which can get people living a normal life.”
Edwards has already paid a “massive” $84,000 for eight injections of the drug through an induction treatment, prior to a stem-cell transplant.
He said he has been extremely lucky to have family financial support to allow him to do this, while he has watched other cancer patients struggle to get time off work for gruelling treatments.
When his cancer comes back, he is looking at potentially hundreds of thousands of dollars to fund it again – a year-long course of the drug can cost $220,000.
“You know how you get that feeling in the pit of your stomach when you get bad news?
“That’s the feeling you sort of walk around with – that feeling of having the wind knocked out of you really.”
Edwards – previously co-owner of a cycle tours business in Martinborough – said he felt he had another 20 years of work and life left in him.
He said daratumumab has been funded in at least 48 other countries as standard practice and he hopes there will be more relief for people like him soon.
Myeloma New Zealand chairwoman Barbara Horne said myeloma was the second-most-common blood cancer in New Zealand and it had been 10 years since a new myeloma medicine had been funded here.
“We hope the funding decision will lead to treatments like daratumumab and carfilzomib being funded,” Horne said.
“Applications for these treatments have been with Pharmac since November 2017 and August 2018 respectively and patients are dying because they cannot access them.”
